Evaluation of the effect of carvedilol in patients with gastrointestinal cancer

Evaluation of the effect of carvedilol in the prevention of cardiovascular complications induced by (5fu (5Fluorouracil) therapy in gastrointestinal cancer (GI) patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200907048646N1

Enrollment

Registered

2020-10-03

Start date

2020-09-20

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancers (Esophageal cancer, Gastric cancer, Pancreatic cancer, Colon cancer). Malignant neoplasm of stomach

Interventions

Intervention 1: Intervention group: Intervention group will receive carvedilol 6.25 mg twice a day two weeks before chemotherapy till one week after chemotherapy. Intervention 2: Control group: in thi

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All gastrointestinal cancer patients in the age range of 18 to 80 years old underwent 5FU therapy. LVEF (left ventricular Ejection Fraction)>50%

Exclusion criteria

Exclusion criteria: Patients with IHD (history of PCI, CABG, and Plavix consumption ) Mitral stenosis and cardiomyopathy ECG changes characteristic to ischemia (ST-elevation more than 0.5mm and ST-depression more than 1 mm) Acute myocardial ischemia at any stage of the study (ECG changes characteristic to ischemia, increased cardiac enzymes, or ischemic manifestations on echocardiography).

Design outcomes

Primary

Measure	Time frame
Percentage of patients with gastrointestinal cancer with cardiac complications. Timepoint: Evaluation of the patient's cardiac condition before the intervention and during chemotherapy at the end of all 3 courses. Method of measurement: ECG, Troponin, Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEffat Iranijam

Ardabil University of Medical Sciences

r.fereydounzadeh@arums.ac.ir+98 45 3325 1401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026